Ongoing treatment(s)-Radiation Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Radiation Posts on Medivizor

Looking for patients with lung cancer to test a new immunotherapy combination

Posted by on Apr 24, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of durvalumab (Imfinzi) and monalizumab to treat patients with solid tumors, including lung cancer. The main outcomes to be measured are tumor response to the treatment and side effects. The details Cancer is one of the leading causes of death worldwide. Chemotherapy is only of limited...

Read More

Adding mFOLFOX6 to the standard treatment for rectal cancer increases cancer response and survival

Posted by on Oct 29, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated whether adding mFOLFOX6 (modified; folinic acid, fluorouracil, and oxaliplatin) chemotherapy after standard chemotherapy and radiotherapy (CRT) and delaying surgery improves cancer response and survival in rectal cancer. Researchers suggest that this treatment increases disease-free survival (DFS;...

Read More

Is there a link between radiation therapy and future heart problems in patients with small-cell lung cancer?

Posted by on Oct 20, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at the link between cardiac (heart) events in the years after radiation therapy in patients with small-cell lung cancer. The authors concluded that there is a long-term risk of cardiac events in patients treated with a combination of radiation therapy and chemotherapy. Some background There have been several reports...

Read More

Comparing daily versus weekly imaging checks in radiation therapy for prostate cancer

Posted by on Aug 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the best timing of treatment verification imaging used in radiation therapy for patients with prostate cancer. This study found that patients undergoing daily imaging had less risk of their cancer returning and had reduced rectal side-effects. Some background One main treatment option for prostate cancer...

Read More

Risk of secondary cancers in patients who have been treated for early stage breast cancer

Posted by on May 17, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to examine the risk of developing a secondary cancer after breast conserving therapy for early stage breast cancer patients. This study found that patients who have been treated for early stage breast cancer do not have a significantly higher risk of secondary cancers.  Some background Women with early stage breast...

Read More

Comparing whole-breast radiotherapy and partial-breast radiotherapy for breast cancer patients who have undergone breast conservation surgery

Posted by on Sep 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the outcomes for patients who received whole and partial breast radiotherapy after undergoing breast conservation surgery. This study concluded that partial breast radiotherapy and lower dose radiotherapy had similar outcomes for patients when compared to whole breast radiotherapy. Some background...

Read More

Is chemoradiation with local removal, better than total surgical removal to treat stage II rectal cancer?

Posted by on Sep 29, 2017 in Colorectal cancer | 0 comments

In a nutshell This study looked survival rates of stage II rectal cancer patients who underwent different treatments. It compared radical surgery versus local excision with added-on chemoradiation. The article concluded that overall survival was not different between the treatments. Some background Radical surgery (RS – complete...

Read More

Durvalumab improves time to disease progression in previously treatment non-small cell lung cancer

Posted by on Sep 21, 2017 in Lung cancer | 0 comments

In a nutshell This study examined the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer. This study concluded that durvalumab delayed time to disease progression. Some background Chemotherapy and radiation are the standard treatment options for stage III non-small cell lung cancer (NSCLC, cancer...

Read More